Markt geschlossen· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
MKSI vs. HOCPY: Which Stock Is the Better Value Option?
PENTAX Medical, a HOYA Group company, today announced the expansion of its partnership with MAGENTIQ EYE, extending an agreement that initially covered the United States to include EMEA, JAPAC and LATAM, further advancing access to AI-enabled endoscopy worldwide. Under the expanded agreement, MAGENTIQ-COLO™ will be integrated into PENTAX Medical's INSPIRA™ EPK-i8020c Video Processor and PENTAX Medical's IMAGINA™ EPK-i5500c Video Processor.
HAYW vs. HOCPY: Which Stock Is the Better Value Option?
FDA clearance puts HOYA (TSE:7741) endoscopy devices in focus HOYA (TSE:7741) has received US FDA clearance for new PENTAX Medical i20c Video Endoscope models, enabling use in US gastrointestinal endoscopy and drawing fresh attention to the stock’s medical device exposure. See our latest analysis for HOYA. The FDA news lands after a mixed period for the stock, with the share price at ¥26,420, a 1-day share price return of 3.0%, a 30-day share price return down 5.7%, and a 1-year total...
Investors may be wondering whether HOYA's share price still offers value after a strong run, or if most of the potential upside is already reflected in the stock. HOYA closed at ¥26,420, with the stock up 0.3% over the last week, down 4.5% over the last month, up 9.5% year to date and up 60.6% over the past year. Recent coverage has focused on HOYA's position in healthcare equipment and related optical technologies, which has kept interest in the stock elevated. This context helps explain...
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Gastrointestinal Endoscopy Devices Market size & share revenue was valued at approximately USD 11.6 Billion in 2025 and is expected to reach USD 12.2 Billion in 2026 and is expected to reach around USD 19.6 Billion by 2035, at a CAGR of 5.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are HOYA Corporatio
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Flexible Endoscope Market size & share revenue was valued at approximately USD 12.7 Billion in 2025 and is expected to reach USD 13.5 Billion in 2026 and is expected to reach around USD 22.7 Billion by 2035, at a CAGR of 6% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Olympus Corporation, Cook Medical
TKR vs. HOCPY: Which Stock Is the Better Value Option?
Here is how Hoya Corp. (HOCPY) and Donnelley Financial Solutions (DFIN) have performed compared to their sector so far this year.
SNX vs. HOCPY: Which Stock Is the Better Value Option?
On October 31, 2025, HOYA Corporation’s board approved a substantial interim dividend of ¥125.00 per share for shareholders as of September 30, 2025, compared to ¥45.00 per share paid a year earlier, with payment set for November 28, 2025. This sharp dividend increase signals management’s confidence in the company’s ongoing financial health and ability to deliver consistent shareholder returns. We’ll explore how HOYA’s significant interim dividend hike frames its investment narrative and...
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.